Peptide Radioligand Therapy: How Lutathera and Pluvicto Work, Who Qualifies, and the Supply Chain Behind Every Dose

Radioligand therapy is a cancer treatment that pairs two things: a molecule that binds to a target on cancer cells, and a radioactive isotope attached to that molecule. The binding molecule is the postal address. The isotope is the payload. When the molecule docks on a cancer cell, most of the radiation lands on the tumor.

When the targeting molecule is a peptide, doctors call the treatment PRRT, short for peptide receptor radionuclide therapy. The first two lutetium-177 radioligand drugs approved in the U.S. were Lutathera, for neuroendocrine tumors in 2018, and Pluvicto, for a type of advanced prostate cancer in 2022. In September 2026, the FDA approved two more lutetium-177 dotatate products for the same tumors as Lutathera: Curium's BEXLUTRY and Lantheus's BRAVNETSA. Lutathera's label calls it a radiolabeled somatostatin analog, which means its targeting molecule mimics the hormone somatostatin. Pluvicto carries a molecule that binds to a protein called PSMA. Both use lutetium-177 (Lu-177) as the radioactive part. According to the Lutathera label, Lu-177's beta particles travel at most 2.2 millimeters in tissue and 0.67 millimeters on average, which keeps the kill zone small.

The therapy differs from external-beam radiation, which aims X-rays at a tumor from outside the body. Radioligand therapy goes in through an IV, circulates, and finds cancer cells that carry its target. It also differs from chemotherapy, which harms dividing cells throughout the body. Radioligand therapy concentrates its dose where the target is present. Healthy tissue still receives some radiation, which is why doctors watch blood counts and kidney function during treatment.

Lutathera (lutetium Lu 177 dotatate). The FDA approved Lutathera on January 26, 2018. Its current label covers adults and children 12 and older with somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs), which start in the pancreas or digestive tract. The dose is 7.4 GBq given every 8 weeks, for four doses. Approval rested on the Phase 3 NETTER-1 trial in 229 patients with midgut neuroendocrine tumors. Patients got either Lutathera plus 30 mg of octreotide or 60 mg of octreotide alone. At the primary analysis, an estimated 65.2% of the Lutathera group was alive without progression at month 20, compared with 10.8% of the control group. Tumors shrank in 18% of patients on Lutathera versus 3% on octreotide alone.

Pluvicto (lutetium Lu 177 vipivotide tetraxetan, also called 177Lu-PSMA-617). The FDA approved Pluvicto on March 23, 2022 for adults with PSMA-positive metastatic castration-resistant prostate cancer (mCRPC) who had already received an androgen-receptor pathway inhibitor and taxane chemotherapy. In the VISION trial of 831 patients, adding Pluvicto to standard care cut the risk of death by 38%, according to Novartis. On March 28, 2025, the FDA expanded the label to patients treated with an androgen-receptor pathway inhibitor who are appropriate to delay chemotherapy. In that trial, PSMAfore, Pluvicto cut the risk of radiographic progression or death by 59%. The final overall survival result favored Pluvicto but was not statistically significant. The dose is 7.4 GBq every 6 weeks, for six doses.

In September 2026, the FDA approved two more products made from lutetium Lu 177 dotatate. That is the same active ingredient as Lutathera. Both are for adults with somatostatin receptor-positive neuroendocrine tumors of the pancreas or digestive tract (GEP-NETs).

Curium's BEXLUTRY came first, on September 14. It was approved through the FDA's 505(b)(2) pathway. Curium says it showed a biological and chemical profile similar to an approved radiopharmaceutical. The company said BEXLUTRY was available right away.

Lantheus's BRAVNETSA followed on September 22. It was approved through the Abbreviated New Drug Application (ANDA) pathway, the route generic drugs use. An ANDA must show the same active ingredient and bioequivalence to an approved drug. Lantheus says BRAVNETSA is the only radiopharmaceutical the FDA has rated therapeutically equivalent to Lutathera. In FDA terms, that means it can be expected to have the same clinical effect and safety profile when used as labeled. Lantheus has not announced a launch date.

Neither company announced a price, so it is too early to say whether patients will pay less. The two companies may also not stay separate. On August 3, 2026, Curium agreed to buy Lantheus in a deal worth up to about $8.0 billion. The deal is expected to close in the first half of 2027 if shareholders and regulators approve it.

For now, the practical change is that more than one company can make lutetium-177 dotatate. Ask your treatment center which product it uses and whether your insurance covers it.

Not every GEP-NET or prostate cancer patient can get these drugs. Doctors first use imaging to confirm that the tumor carries the target.

Lutathera is for somatostatin receptor-positive tumors. FDA-approved PET agents for finding these receptors include NETSPOT, a kit for making gallium-68 dotatate that was approved in 2016, and Detectnet, a copper-64 dotatate scan approved in 2020. The NETTER-1 trial used an older receptor scan called OctreoScan.

For Pluvicto, the label says to select patients using Locametz or another approved PSMA PET agent. Locametz is a PSMA scan for prostate cancer. It is not used to qualify patients for Lutathera, which targets a different receptor.

The scan decides eligibility for a simple reason. If the tumor does not carry the target, the drug has nothing to bind to.

For Lutathera, patients first get anti-nausea medicine. Then an IV of amino acids (L-lysine and L-arginine) starts 30 minutes before the dose and runs during the infusion and for at least 3 hours after it. The Lutathera dose itself runs over 30 to 40 minutes. Pluvicto can be given as an injection over about 1 to 10 minutes or as an infusion of about 30 minutes, depending on the method the center uses.

After a dose, you give off low levels of radiation for a while. The Pluvicto label tells patients to stay more than 3 feet from other people for 2 days and from children and pregnant women for 7 days. It also says to sleep in a separate room from other adults for 3 days, from children for 7 days, and from pregnant women for 15 days. The Lutathera label asks patients to limit radiation exposure to people at home. It notes that radiation can show up in urine for up to 30 days.

Both labels warn about effects on the blood and kidneys. Pluvicto can cause severe drops in blood counts and severe kidney toxicity. Its most common side effects include low blood counts, fatigue, dry mouth, and nausea. For Lutathera, the most common severe side effects and lab changes included low lymphocyte counts, raised liver enzymes, vomiting, and nausea.

Novartis lists Pluvicto's wholesale acquisition cost (WAC), which is the list price before discounts, at $51,168.13 per dose as of January 7, 2026. Its cost page says very few patients pay the list price. It also says about 80% of patients with insurance pay $0 per infusion. Administration fees can add to the bill.

This article could not confirm Lutathera's current list price from a primary source. Before starting either drug, ask the treatment center and your insurer for a cost estimate, and ask whether a manufacturer support program applies to you.

Lu-177 has a half-life of about 6.6 days. Half its radioactivity is gone in under a week, and after 14 days less than a quarter remains. That makes these drugs impossible to stockpile like pills.

The labels set short shelf lives: 72 hours from the calibration time for Lutathera and 120 hours, or 5 days, for Pluvicto. Each dose has to be made, tested, and shipped to the treatment center inside that window. A dose that misses its window cannot be used, and the patient's treatment moves. When demand outruns production, a waitlist forms.

Pluvicto's launch in March 2022 is the clearest example. By spring 2023, only one FDA-approved site made the drug for U.S. commercial use, in Ivrea, Italy. A May 2023 essay on KevinMD described waits of at least three months. It also cited an estimate that one in 20 patients died while waiting.

The FDA approved Novartis's Millburn, New Jersey plant for U.S. commercial production in late April 2023. On October 26, 2023, Novartis said it had more than doubled weekly production since May and that supply was unconstrained. It also said the FDA had classified the shortage as resolved. By then, more than 200 centers were ordering Pluvicto, and about 130 more were planned. A new Indianapolis plant had started clinical production and was awaiting FDA approval to make commercial doses. By March 2025, Novartis described five radioligand manufacturing sites, including one under development in Carlsbad, California.

The Pluvicto label says radioactive drugs should be used by or under the control of health care providers trained in their safe handling, with training approved by the appropriate government agency. So treatment happens at sites set up for radioactive drugs, not at every infusion center. In March 2025, Novartis said about 600 U.S. sites could deliver its radioligand therapies.

The nearest site may still be some distance away. Ask your oncologist where they refer patients and how long the wait is from the qualifying scan to the first dose.

On September 21, 2026, Telix Pharmaceuticals announced a merger with Germany's ITM Isotope Technologies Munich. Telix will pay $1.65 billion upfront plus up to $700 million more. Up to $250 million depends on FDA approvals of ITM-11 (177Lu-edotreotide) in three neuroendocrine tumor indications. Up to $450 million depends on ITM-11 sales in 2030. Telix says ITM-11 has completed Phase 3 development.

Telix calls ITM the world's leading supplier of therapeutic radioisotopes and the only producer of commercial-grade Lu-177 at global scale. ITM also produces actinium-225 and terbium-161. Telix describes the combined company as vertically integrated, meaning it would make isotopes, develop drugs, and distribute them. Telix's own pipeline includes three therapy candidates, TLX591, TLX101, and TLX250, which it says are in registration trials.

For patients, the key issue is supply. The Pluvicto shortage showed how one bottleneck can delay care for months. Whether the merger improves access to Lu-177 and newer isotopes will not be clear until after the deal closes. Closing requires Telix shareholder approval and other customary conditions.

Lu-177 emits beta particles. Actinium-225 (Ac-225) emits alpha particles instead. Alpha particles travel only 40 to 100 micrometers in tissue, but they deposit far more energy along the way: about 80 keV per micrometer, compared with about 0.2 for beta particles, according to a 2024 review in Theranostics. Ac-225 has a half-life of 9.92 days. Supply is the main limit. The same review says the parent isotope, thorium-229, comes from three sources, including Oak Ridge National Laboratory, and that this supply cannot yet meet routine demand. It adds that accelerator-made Ac-225 has the potential to fill the gap.

Early human data are promising but small. At the 2026 ASCO Genitourinary Cancers Symposium, Bayer reported that its Phase 1 PAnTHa study of an Ac-225 PSMA agent had no dose-limiting toxicities in men with mCRPC who had already received hormone therapy and taxane chemotherapy. At one dose level, 67% of patients had PSA drops of at least 90%. Side effects were mostly mild, such as dry mouth and nausea.

Terbium-161 (Tb-161) emits beta particles like Lu-177, plus short-range conversion and Auger electrons. A 2024 review in the Journal of Nuclear Medicine cited dosimetry estimates that Tb-161 delivers about 2.6 to 3.6 times more radiation than Lu-177 to single tumor cells. That matters for tiny tumor deposits that scans cannot see. Trials include the Phase 1/2 VIOLET study in 30 men with mCRPC.

Newer Lu-177 drugs are also moving. ITM-11 has completed Phase 3, and Telix lists three therapy candidates in registration trials.

• Does my cancer type and stage fit the approved label for either drug, or is there an open clinical trial that would take me?
• Which scan decides whether I qualify, and where do I get it done?
• How long is the wait between the qualifying scan and the first dose at the site closest to me?
• Which treatment site do you refer patients to?
• What will my out-of-pocket cost be under my insurance, and does a manufacturer support program apply?
• If the standard drug is not an option or stops working, are Ac-225 or Tb-161 clinical trials open to me?
• How will my blood counts and kidney function be checked during the four- or six-dose course?

Radioligand therapy is established treatment for some patients. Two Lu-177 drugs are on the U.S. market, and more are in late-stage trials. For many patients, the practical hurdles are getting the right scan, reaching a treatment site, and getting a dose delivered inside its short shelf life.

The Telix–ITM merger is a bet that controlling isotope supply matters. Whether it helps patients depends on the deal closing and on how quickly the combined company scales up Lu-177, Ac-225, and Tb-161. For patients with a neuroendocrine tumor or mCRPC today, the steps are simpler: ask whether you qualify, get the scan, find the treatment site, check the cost, and talk with your oncologist about timing.

Correction (September 23, 2026): An earlier version of this article listed Locametz as an imaging agent for Lutathera eligibility; Locametz is a PSMA imaging agent used for Pluvicto. We also fixed five other errors. ITM-11 is 177Lu-edotreotide, not a somatostatin receptor antagonist, and Telix's announcement does not mention an FDA rejection. NETTER-1 compared Lutathera plus 30 mg of octreotide with 60 mg of octreotide alone. The final PSMAfore survival result was not statistically significant; it was not immature. Alpha particles carry about 400 times the energy per micrometer of beta particles, not 100 times. Novartis's Indianapolis plant was awaiting approval for commercial doses in October 2023. We removed figures and claims we could not trace to a primary source. These included regional center counts, eligibility rates, and a Lutathera list price. They also included course cost totals, Medicare billing claims, and a claim about Ac-225 results after Pluvicto. We also replaced peptide profile links for Lutathera and Pluvicto that did not work.

Update (September 25, 2026): We added the FDA's September 2026 approvals of BEXLUTRY and BRAVNETSA. The original version said Lutathera and Pluvicto were the only two lutetium-177 radioligand drugs approved in the U.S.; BEXLUTRY had already been approved on September 14, a week before this article was published.